Journey Medical (DERM) financial statements
Journey Medical reported revenue of $61M in fiscal 2025, up 6.6% a year over 5 years.
Net income was -$11M and the operating margin -13.3%, against 17.6% in 2020.
The diluted share count rose 126% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Journey Medical's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $45M | $63M | $71M | $60M | $55M | $61M |
| Cost of revenue | $15M | $32M | $31M | $23M | $21M | $21M |
| Gross profit | $30M | $31M | $40M | $37M | $34M | $40M |
| Research and development | — | $3M | $11M | $8M | $10M | $480,000 |
| Selling, general and admin | $22M | $40M | $59M | $44M | $40M | $44M |
| Operating income | $8M | -$35M | -$28M | -$2M | -$14M | -$8M |
| Interest expense | $698,000 | $7M | $2M | $2M | $3M | $4M |
| Pre-tax income | $7M | -$42M | -$30M | -$4M | -$15M | -$11M |
| Income tax | $2M | $2M | $63,000 | $221,000 | $61,000 | $60,000 |
| Net income | $5M | -$44M | -$30M | -$4M | -$15M | -$11M |
| EPS (diluted) | $0.49 | -$4.32 | -$1.69 | -$0.21 | -$0.72 | -$0.47 |
| Diluted shares | 11M | 10M | 18M | 18M | 20M | 24M |
| Gross margin | 67.2% | 49.2% | 56.7% | 61.6% | 62.1% | 65.8% |
| Operating margin | 17.6% | -55.2% | -38.8% | -3.5% | -24.8% | -13.3% |
| Net margin | 11.9% | -69.7% | -41.7% | -6.5% | -26.6% | -18.7% |
Balance sheet
Fiscal years, from Journey Medical's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $8M | $49M | $32M | $27M | $20M | $24M |
| Receivables | $24M | $23M | $28M | $15M | $10M | $30M |
| Inventory | $1M | $10M | $14M | $10M | $14M | $10M |
| Total current assets | $35M | $84M | $78M | $56M | $48M | $67M |
| Total assets | $52M | $97M | $105M | $77M | $80M | $95M |
| Total current liabilities | $28M | $52M | $67M | $42M | $35M | $37M |
| Long-term debt | — | — | $20M | $15M | $25M | $25M |
| Total liabilities | $42M | $55M | $88M | $56M | $60M | $63M |
| Shareholders' equity | $10M | $42M | $17M | $20M | $20M | $32M |
| Net debt | -$8M | -$49M | -$12M | -$13M | $5M | $1M |
Cash flow
Fiscal years, from Journey Medical's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $5M | -$2M | -$14M | $5M | -$9M | -$12M |
| Capital spending | — | — | $20M | $5M | $15M | — |
| Free cash flow | — | — | -$34M | $240,000 | -$24M | — |
| Stock-based compensation | $153,000 | $2M | $4M | $3M | $6M | $6M |
| Free cash flow margin | — | — | -47.2% | 0.4% | -43.8% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DERM.
Open DERM in InvestinglyQuestions
What was Journey Medical's revenue in 2025?
$61M in fiscal 2025, from its 10-K filing.
From Journey Medical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.